191 related articles for article (PubMed ID: 36980269)
1. Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent K
Scala R; Maqoud F; McClenaghan C; Harter TM; Perrone MG; Scilimati A; Nichols CG; Tricarico D
Cells; 2023 Mar; 12(6):. PubMed ID: 36980269
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular consequences of KATP overactivity in Cantu syndrome.
Huang Y; McClenaghan C; Harter TM; Hinman K; Halabi CM; Matkovich SJ; Zhang H; Brown GS; Mecham RP; England SK; Kovacs A; Remedi MS; Nichols CG
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089727
[TBL] [Abstract][Full Text] [Related]
3. Consequences of SUR2[A478V] Mutation in Skeletal Muscle of Murine Model of Cantu Syndrome.
Scala R; Maqoud F; Zizzo N; Passantino G; Mele A; Camerino GM; McClenaghan C; Harter TM; Nichols CG; Tricarico D
Cells; 2021 Jul; 10(7):. PubMed ID: 34359961
[TBL] [Abstract][Full Text] [Related]
4. Rapid Characterization of the Functional and Pharmacological Consequences of Cantú Syndrome K
Gao J; McClenaghan C; Matreyek KA; Grange DK; Nichols CG
J Pharmacol Exp Ther; 2023 Sep; 386(3):298-309. PubMed ID: 37527933
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiological Consequences of KATP Channel Overactivity and Pharmacological Response to Glibenclamide in Skeletal Muscle of a Murine Model of Cantù Syndrome.
Scala R; Maqoud F; Zizzo N; Mele A; Camerino GM; Zito FA; Ranieri G; McClenaghan C; Harter TM; Nichols CG; Tricarico D
Front Pharmacol; 2020; 11():604885. PubMed ID: 33329006
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic Acid as a Novel Dual Blocker of KIR6.1/2-SUR2 Subunits of ATP-Sensitive K
Maqoud F; Scala R; Tragni V; Pierri CL; Perrone MG; Scilimati A; Tricarico D
Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575427
[TBL] [Abstract][Full Text] [Related]
7. Differential mechanisms of Cantú syndrome-associated gain of function mutations in the ABCC9 (SUR2) subunit of the KATP channel.
Cooper PE; Sala-Rabanal M; Lee SJ; Nichols CG
J Gen Physiol; 2015 Dec; 146(6):527-40. PubMed ID: 26621776
[TBL] [Abstract][Full Text] [Related]
8. Kir6.1-dependent K
Davis MJ; Kim HJ; Zawieja SD; Castorena-Gonzalez JA; Gui P; Li M; Saunders BT; Zinselmeyer BH; Randolph GJ; Remedi MS; Nichols CG
J Physiol; 2020 Aug; 598(15):3107-3127. PubMed ID: 32372450
[TBL] [Abstract][Full Text] [Related]
9. Conserved functional consequences of disease-associated mutations in the slide helix of Kir6.1 and Kir6.2 subunits of the ATP-sensitive potassium channel.
Cooper PE; McClenaghan C; Chen X; Stary-Weinzinger A; Nichols CG
J Biol Chem; 2017 Oct; 292(42):17387-17398. PubMed ID: 28842488
[TBL] [Abstract][Full Text] [Related]
10. Lymphatic contractile dysfunction in mouse models of Cantú Syndrome with K
Davis MJ; Castorena-Gonzalez JA; Kim HJ; Li M; Remedi M; Nichols CG
Function (Oxf); 2023; 4(3):zqad017. PubMed ID: 37214333
[TBL] [Abstract][Full Text] [Related]
11. Cantu syndrome-associated SUR2 (ABCC9) mutations in distinct structural domains result in K
McClenaghan C; Hanson A; Sala-Rabanal M; Roessler HI; Josifova D; Grange DK; van Haaften G; Nichols CG
J Biol Chem; 2018 Feb; 293(6):2041-2052. PubMed ID: 29275331
[TBL] [Abstract][Full Text] [Related]
12. Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity.
McClenaghan C; Huang Y; Yan Z; Harter TM; Halabi CM; Chalk R; Kovacs A; van Haaften G; Remedi MS; Nichols CG
J Clin Invest; 2020 Mar; 130(3):1116-1121. PubMed ID: 31821173
[TBL] [Abstract][Full Text] [Related]
13. Cardiac sulfonylurea receptor short form-based channels confer a glibenclamide-insensitive KATP activity.
Pu JL; Ye B; Kroboth SL; McNally EM; Makielski JC; Shi NQ
J Mol Cell Cardiol; 2008 Jan; 44(1):188-200. PubMed ID: 18001767
[TBL] [Abstract][Full Text] [Related]
14. Kir6.1 and SUR2B in Cantú syndrome.
McClenaghan C; Nichols CG
Am J Physiol Cell Physiol; 2022 Sep; 323(3):C920-C935. PubMed ID: 35876283
[TBL] [Abstract][Full Text] [Related]
15. A Cantú syndrome mutation produces dual effects on KATP channels by disrupting ankyrin B regulation.
Crespo-García T; Rubio-Alarcón M; Cámara-Checa A; Dago M; Rapún J; Nieto-Marín P; Marín M; Cebrián J; Tamargo J; Delpón E; Caballero R
J Gen Physiol; 2023 Jan; 155(1):. PubMed ID: 36287534
[TBL] [Abstract][Full Text] [Related]
16. Kir6.1- and SUR2-dependent KATP overactivity disrupts intestinal motility in murine models of Cantú syndrome.
York NW; Parker H; Xie Z; Tyus D; Waheed MA; Yan Z; Grange DK; Remedi MS; England SK; Hu H; Nichols CG
JCI Insight; 2020 Nov; 5(23):. PubMed ID: 33170808
[TBL] [Abstract][Full Text] [Related]
17. ATP-sensitive potassium currents from channels formed by Kir6 and a modified cardiac mitochondrial SUR2 variant.
Aggarwal NT; Shi NQ; Makielski JC
Channels (Austin); 2013; 7(6):493-502. PubMed ID: 24037327
[TBL] [Abstract][Full Text] [Related]
18. Complex consequences of Cantu syndrome SUR2 variant R1154Q in genetically modified mice.
Zhang H; Hanson A; de Almeida TS; Emfinger C; McClenaghan C; Harter T; Yan Z; Cooper PE; Brown GS; Arakel EC; Mecham RP; Kovacs A; Halabi CM; Schwappach B; Remedi MS; Nichols CG
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33529173
[TBL] [Abstract][Full Text] [Related]
19. K(ATP) channel gain-of-function leads to increased myocardial L-type Ca(2+) current and contractility in Cantu syndrome.
Levin MD; Singh GK; Zhang HX; Uchida K; Kozel BA; Stein PK; Kovacs A; Westenbroek RE; Catterall WA; Grange DK; Nichols CG
Proc Natl Acad Sci U S A; 2016 Jun; 113(24):6773-8. PubMed ID: 27247394
[TBL] [Abstract][Full Text] [Related]
20. KATP channel subunits in rat dorsal root ganglia: alterations by painful axotomy.
Zoga V; Kawano T; Liang MY; Bienengraeber M; Weihrauch D; McCallum B; Gemes G; Hogan Q; Sarantopoulos C
Mol Pain; 2010 Jan; 6():6. PubMed ID: 20102598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
